Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brentuximab vedotin - Seattle Genetics/Takeda

Drug Profile

Brentuximab vedotin - Seattle Genetics/Takeda

Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seattle Genetics; Stanford University; Takeda; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Non-Hodgkin's lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Hodgkin's disease; Mycosis fungoides
  • Registered Peripheral T-cell lymphoma; T-cell lymphoma
  • Phase II Adult T-cell leukaemia-lymphoma; Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Mastocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Sezary syndrome
  • Phase I/II Diffuse scleroderma
  • No development reported Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours; Systemic lupus erythematosus

Most Recent Events

  • 29 Oct 2019 Seattle Genetics initiates enrolment in a clinical trial for Hodgkin's lymphoma and Peripheral-T-cell-lymphoma (Monotherapy) before October 2019
  • 29 Oct 2019 Seattle Genetics initiates enrolment in a clinical trial for Hodgkin's lymphoma and Peripheral-T-cell-lymphoma (Recurrent) before October 2019
  • 29 Oct 2019 Seattle Genetics initiates enrolment in a phase II trial for Hodgkin's lymphoma (Late-stage disease, Combination therapy) before October 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top